Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acceptance of low-THC/high-CBD versus high-THC cannabis in patients with schizophrenia
NL-OMON44002Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of bediol and bedrobinol in schizophrenia, Schizophrenia Spectrum Disorders (SSD) and cannabis use disorder (CUD) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Acceptance of Bediol as preferred alternative and Reason for preference. Started Dec 2016; status: active, not recruiting.
02
Drugs
bediolbedrobinol
03
Conditions
schizophreniaSchizophrenia Spectrum Disorders (SSD)cannabis use disorder (CUD)
Beyond the preview
Go deeper on NL-OMON44002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44002.